Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients.
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000016966
- Lead Sponsor
- Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with advanced diabetic complications. 2)Patients with to the contraindication of GLP-1 receptor agonist (Victoza subcutaneous injection18mg) (Liraglutide) 3)Patients with to the contraindication of the long acting insulin analog formulation (Tresiba Injection) (Degludec) 4)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method